Max Healthcare Q2 Results Review - Inline Ebitda; Aided By Healthy Utilisation: Prabhudas Lilladher

Prabhudas Lilladher Report

Max Healthcare Institute Ltd. reported Ebitda of Rs 4 billion (up 9% QoQ) versus our estimate of Rs 3.9 billion.

Overall occupancy stood at 78% versus 74% in Q1 on seasonality, while average revenue per occupied bed remained steady QoQ at Rs 66,000 due to medical mix obligation.

The company became net cash positive by Rs 420 million versus Rs 2.1 billion of net debt in Q1. Operational efficiency has also been commendable, especially in competitive markets like national capital region.

Max Healthcare has shown phenomenal growth in past two years and we expect this momentum to continue given-

1. strong expansion plans,

2. improving payor mix and

3. scale up in labs.

Our FY23E and FY24E Ebitda broadly remains unchanged. We expect 17% Ebitda compound annual growth rate over FY22-25E.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.